Coriell is using state of the art CRISPR/Cas9 technology to edit disease-specific iPSC lines from our repositories to generate isogenic iPSC lines for the broad research community. These lines offer researchers a better tool to study a mutation of interest without influence from different genetic backgrounds when comparing disease state and the control (apparently healthy state). 

Coriell is planning to offer this service to our customers in the near future.